Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 2;8(1):e2453819.
doi: 10.1001/jamanetworkopen.2024.53819.

Atrial Fibrillation and Retinal Stroke

Affiliations

Atrial Fibrillation and Retinal Stroke

Jay B Lusk et al. JAMA Netw Open. .

Abstract

Importance: Atrial fibrillation (AF) is the most common, chronic, cardiac arrythmia in older US adults. It is not known whether AF is independently associated with increased risk of retinal stroke (central retinal artery occlusion), a subtype of ischemic stroke that causes severely disabling visual loss in most cases and is a harbinger of further vascular events.

Objective: To determine whether there is an association between AF and retinal stroke.

Design, setting, and participants: This retrospective cohort study was performed between July 2023 and May 2024 using computerized inpatient, outpatient, emergency department, and skilled nursing facility claims files for a 5% sample of US fee-for-service Medicare beneficiaries aged 66 years and older between 2000 and 2020. Follow-up ended at death, conclusion of fee-for-service Medicare coverage, end of the study period, or loss to follow-up of 85% of the study cohort.

Exposure: AF, based on validated International Classification of Diseases, Ninth Revision, Clinical Modification and International Statistical Classification of Diseases, Tenth Revision, Clinical Modification diagnosis codes.

Main outcomes and measures: The primary end point was incident retinal stroke in the primary diagnostic position of a single claim in any venue of care. Secondary end points included retinal stroke in any position of a single claim, 1 positive control end point (cerebral ischemic stroke), and 4 negative control end points (central retinal vein occlusion, urinary tract infection, humeral fracture, and cataract). Unadjusted and adjusted hazard ratios (HRs) and rate differences were computed across matched and overlap-weighted cohorts with and without AF (defined as 1 inpatient claim or 2 outpatient claims within a 365-day period).

Results: In total, 1 090 144 patients (591 400 female [54.3%]; mean [SD] age, 76.92 [7.09] years) were included in the study; 545 072 patients had AF and 545 072 were matched controls. The median (IQR) follow-up was 45 (18 to 90) months. In total, 1333 patients with AF (rate, 0.55 per 1000 person-years) and 1082 AF-free matched controls (rate, 0.50 per 1000 person-years) experienced retinal stroke. The cause-specific, adjusted HR of retinal stroke after overlap weighting was 1.14 (95% CI, 1.02 to 1.28; adjusted rate difference, 0.05 [95% CI, -0.01 to 0.11]). AF was associated with cerebral ischemic stroke (adjusted HR, 1.73 [95% CI, 1.69 to 1.76]; adjusted rate difference, 10.11 [95% CI, 9.72 to 10.49]). Of 4 prespecified negative control end points, AF was not associated with central retinal vein occlusion but was associated with urinary tract infection, cataract, and humeral fracture.

Conclusions and relevance: In this cohort study of Medicare beneficiaries aged 66 years and older, AF was independently associated with retinal stroke. The magnitude of the association was small, and a contribution from residual, unmeasured confounding could not be excluded.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Wilson reported receiving grants from AstraZeneca paid to her institution outside the submitted work. Dr Schrag reported receiving personal fees from the REVISION trial, which is related to central retinal artery occlusion treatment and is funded by the German Federal Ministry of Education and Research (grant 01KG2014), for serving as chair of the data safety monitoring board, and receiving personal fees from Labaton Sucharow, Raymond James, Guidepoint, and Greycourt and Co outside the submitted work. Dr Poli reported receiving grants from BMS/Pfizer for the ATTICUS trial, nonfinancial support from Boehringer-Ingelheim for the REVISION trial, grants from Daiichi Sankyo for the SPOCT-DOAC 1 study, grants from European Union for the PROOF trial, grants from German Federal Joint Committee Innovation Fund for the APICES project, grants from German Federal Ministry of Education and Research for the REVISION trial, nonfinancial support from Helena Laboratories and Werfen for the SPOCT-DOAC 1 study, and personal fees from Alexion, AstraZeneca, Bayer, Boehringer-Ingelheim, BMS/Pfizer, Daiichi Sankyo, Portola, and Werfen outside the submitted work. Dr Piccini reported receiving grants from American Heart Association, Abbott, Boston Scientific, iRhythm, and Bayer; and personal fees from Medtronic, Abbott, and Boston Scientific outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Flowchart of Patient Selection for Inclusion in the Study
AF indicates atrial fibrillation; CE, continuous enrollment; and CRAO, central retinal artery occlusion.
Figure 2.
Figure 2.. Cumulative Incidence of the Primary End Point According to Atrial Fibrillation (AF) Status
Shaded areas denote 95% CIs. HR indicates hazard ratio.
Figure 3.
Figure 3.. Cumulative Incidence of the Secondary End Points
A, Graph shows incidence of central retinal artery occlusion (CRAO) in any diagnostic position. B, Graph shows incidence of any retinal artery occlusion (RAO; retinal stroke, branch retinal artery occlusion, and any retinal artery occlusion). Shaded areas denote 95% CIs. AF indicates atrial fibrillation; and HR, hazard ratio.

References

    1. Go AS, Hylek EM, Phillips KA, et al. . Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370-2375. doi:10.1001/jama.285.18.2370 - DOI - PubMed
    1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983-988. doi:10.1161/01.STR.22.8.983 - DOI - PubMed
    1. Lin HJ, Wolf PA, Kelly-Hayes M, et al. . Stroke severity in atrial fibrillation: the Framingham Study. Stroke. 1996;27(10):1760-1764. doi:10.1161/01.STR.27.10.1760 - DOI - PubMed
    1. Lamassa M, Di Carlo A, Pracucci G, et al. . Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke. 2001;32(2):392-398. doi:10.1161/01.STR.32.2.392 - DOI - PubMed
    1. Benjamin EJ, Go AS, Desvigne-Nickens P, et al. . Research priorities in atrial fibrillation screening: a report from a National Heart, Lung, and Blood Institute virtual workshop. Circulation. 2021;143(4):372-388. doi:10.1161/CIRCULATIONAHA.120.047633 - DOI - PMC - PubMed

Publication types